NCT03178201 is a Phase 2 clinical trial of TGR-1202 in Follicular Lymphoma, sponsored by Columbia University.

Who is sponsoring NCT03178201?

NCT03178201 is sponsored by Columbia University.

What drugs are being tested in NCT03178201?

Interventions in NCT03178201: TGR-1202.

What condition does NCT03178201 study?

NCT03178201 studies Follicular Lymphoma.

Is NCT03178201 still recruiting?

NCT03178201 is currently terminated. Last updated 16 July 2021.

Are results published for NCT03178201?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2021-07-16 · How we verify

NCT03178201

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

TGR1202 in Relapsed and Refractory Follicular Lymphoma

Terminated Phase 2 Results posted Last updated 16 July 2021

What this trial tests

Phase 2 trial testing TGR-1202 in Follicular Lymphoma in 5 participants. Terminated before completion.

Timeline

20 August 2017

Primary endpoint
30 June 2020

30 June 2020

Quick facts

Lead sponsor	Columbia University
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	5
Start date	20 August 2017
Primary completion	30 June 2020
Estimated completion	30 June 2020
Sites	1 location across United States

Drugs / interventions tested

TGR-1202 — full drug profile →

Conditions studied

Follicular Lymphoma — all drugs for Follicular Lymphoma →

Sponsor

Columbia University

Who can join

18 and older, any sex, with Follicular Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective is to determine the overall response rate (ORR) of TGR-1202 in R/R FL. Secondary Objectives * Determine the genetic and other novel biological markers that may be predictive of response or resistance to TGR-1202 in patients with relapsed or refractory FL. * Describe the Progression Free Survival (PFS), Duration of Response (DoR) after treatment with TGR-1202. * Describe the number of dose delays and dose reductions and other safety profile.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Role of PI3K/AKT pathway in cancer: the framework of malignant behavior.
Jiang N, Dai Q, Su X, Fu J, et al · · 2020 · cited 419× · PMID 32333246 · DOI 10.1007/s11033-020-05435-1

Verify or expand the search:

Other trials of TGR-1202

Trials testing the same drug.

NCT03207256 — Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment · Phase 2 · terminated
NCT02867618 — Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma · Phase 1, PHASE2 · terminated
NCT02612311 — Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chr · Phase 3 · terminated

Other recruiting trials for Follicular Lymphoma

Currently open trials in the same condition.

NCT07128641 — Odronextamab in Low Tumor Volume Advanced FL · Phase 2 · recruiting
NCT06792825 — HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL · Phase 2 · recruiting
NCT06911502 — A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Ch · Phase 3 · recruiting
NCT07126678 — Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular Lymphoma · NA · recruiting
NCT06860880 — Combating Cancer-Related Fatigue: A Personalized Supportive Care Program · NA · recruiting

Other Columbia University trials

Trials by the same sponsor.

NCT06558422 — Human Models of Selective Insulin Resistance: Pancreatic Clamp · Phase 1 · not yet recruiting
NCT07264582 — HIV/STI/HCV Testing and Overdose Prevention Among Survivors of Sex Trafficking · NA · not yet recruiting
NCT05992415 — Know Your Pressures NYC · NA · not yet recruiting
NCT05645211 — The AgRP and GH/IGF-1 Axis in Children · not yet recruiting
NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03178201 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Columbia University
Last refreshed: 16 July 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03178201.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing